also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences


Gilead Sciences


Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

Looking for leads, investment insights, or competitive intelligence?


John F. Milligan

CEO Title

President, Chief Executive Officer & Director


Health Care



HQ Location

Foster City, CA

Years on Fortune 500 List




Profile provided by S&P Global.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$30,390-6.9%
Profits ($M)$13,501.0-25.4%
Assets ($M)$56,977
Total Stockholder Equity ($M)$18,887
Market Value — as of March 31, 2017 ($M)$88,788
Profit Ratios
Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)9.94
EPS % Change (from 2015)-16.5%
EPS % Change (5 year annual rate)41.1%
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2016)-27.6%
Total Return to Investors (5 year, annualized)29.4%
Total Return to Investors (10 year, annualized)16.4%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

New Zealand Is About to Make the Revolutionary HIV Prevention Drug Truvada Almost Free

The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.

Read More →
The Diseases We Aren't Curing—And Why

Drug makers are flocking to certain treatment types. Why do others get left behind?

Read More →
Why Analysts Are Calling Celgene's $9 Billion Juno Acquisition a 'Smart' Biotech Deal

Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.

Read More →
2017 Saw the Most New Drugs Approved in Over 20 Years

The FDA approved 46 novel drugs in 2017 versus 22 in 2016.

Read More →